### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

	L	-ugai i ili	ng. 00								
CORCEPT Form 4 March 20, 2	THERAPEUTIC:	S INC									
FORM		CT A TEC	CECU	DITIES		<b>• • • • • •</b>		MARCION		PROVAL	
	UNITED	SIAIES					NGE CU	MMISSION	OMB Number:	3235-0287	
	k this box								Expires:	January 31,	
subject t Section	if no longer   STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF     subject to   Section 16.     Form 4 or   Form 5     Form 5   Filed pursuant to Section 16(a) of the Securities Exchange Act of 1034							Estimated a burden hour response			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
ENRIGHT PATRICK G Symbol			ool Is				5. Relationship of Reporting Person(s) to ssuer				
	CORCEPT THERAPEUTICS INC   (Check all applicable)     [CORT]   (Check all applicable)						)				
					ve title 0% Owner Other (specify						
C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220											
	(Street)		4. If Am	endment, D	ate Original		6	. Individual or Joi	nt/Group Filin	g(Check	
Filed(Month/Day/Year)   Applicable Line)     _X_Form filed by One Reporting Person											
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of	2. Transaction Date	2A. Deem					-	5. Amount of		7. Nature of	
Security (Instr. 3)	(Month/Day/Year)	Execution any (Month/Da			omr Disposed (Instr. 3, 4 a	d of (I	<b>)</b> )	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D)	Price \$	(Instr. 3 and 4)			
Common Stock	03/16/2017			S	264,650	D	φ 9.9396 (1)	5,721,372 <u>(2)</u>	Ι	By LVP (3)	
Common Stock	03/16/2017			S	5,305	D	\$ 9.9381 (1)	114,675 <u>(2)</u>	Ι	By LCA (3)	
Common Stock								272,281 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	3	Date	7. Title Amoun Underl Securit (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
		Director	10% Owner	Officer	Other		
ENRIGHT PATRICK G C/O LONGITUDE CAPITA 800 EL CAMINO REAL, SU MENLO PARK, CA 94025	Х						
Signatures							
/s/ Patrick G.	03/20/2017						

Enright	03/20/2017
<u>**</u> Signature of Reporting Person	Date

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from \$9.855 to \$10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and (1) Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution

(2) by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.

### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole

(3) general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.